Welcome to our dedicated page for Terumo news (Ticker: TRUMY), a resource for investors and traders seeking the latest updates and insights on Terumo stock.
The news page for TERUMO CORP UNSP/ADR (TRUMY) aggregates company-related announcements tied to Terumo Corporation, a medical technology company active in vascular intervention, neurovascular devices, blood and cell technologies, and digital health tools. Recent releases highlight developments from divisions and subsidiaries such as Terumo Neuro, Terumo Interventional Systems, Terumo Health Outcomes, and Terumo Blood and Cell Technologies.
Readers can find updates on neurovascular and stroke treatment devices, including Terumo Neuro’s SOFIA 88 Neurovascular Support Catheter and its broader stroke portfolio of aspiration catheters, retrieval devices, balloon guide catheters, microcatheters, and guidewires. News also covers regulatory milestones such as FDA approval for a dual-layer micromesh carotid stent system and data presentations at professional conferences.
Coverage extends to interventional cardiology and peripheral interventions through Terumo Interventional Systems, with announcements on products like the ROADSAVER Carotid Stent System and R2P NaviCross peripheral support catheter. These items illustrate Terumo’s focus on minimally invasive entry site management, lesion access, and endovascular treatment technologies.
Additional articles describe digital health and decision support initiatives from Terumo Health Outcomes, including the ePRISM precision medicine platform and collaborations around Medis QFR software for coronary physiology assessment. Terumo Blood and Cell Technologies contributes news on blood and cell therapy technologies, such as the Spectra Optia Apheresis System and research on automated red blood cell exchange for sickle cell disease.
Investors and healthcare professionals can use this news feed to follow product launches, clinical data, partnerships, and technology updates associated with the TRUMY ADR’s underlying company. Bookmark this page to access an organized view of Terumo-related press releases and developments as they are reported.
Terumo Corporation (TSE: 4543) has pledged an additional USD 1 million to the COVID-19 Solidarity Response Fund for the WHO, marking its second contribution since April 2020. This donation aims to bolster vaccine equity efforts in low-income countries, which have received less than 1% of global vaccine distributions. The fund, over its first year, has mobilized USD 250 million for essential COVID-19 research, treatments, and supplies. Shinjiro Sato, CEO, emphasized the importance of equitable healthcare during these challenging times.
Terumo Blood and Cell Technologies and CSL Plasma have announced a collaboration to develop a new plasma collection platform at CSL Plasma's U.S. collection centers. A clinical trial for the investigational plasmapheresis device commenced in April 2021. The introduction of this platform is contingent on U.S. FDA device clearance, with further details to follow. Plasma collected plays a crucial role in therapies for life-threatening conditions, including immune deficiencies and hemophilia. CSL Plasma operates over 300 centers globally, providing vital therapies to patients.
Terumo has launched its Global Therapeutic Interventional Oncology team as of April 1, 2021, aiming to enhance cancer treatment solutions. This specialized team focuses on Medical Strategy, Research & Development, and Software Development, and will be led by Laurent Domas. With a growing demand for minimally invasive treatments, Terumo plans to extend its Holmium platform in regions including the US and China, addressing the rise in cancer cases.
Terumo Corporation (TSE: 4543) announced its definitive agreement to acquire all assets of Health Outcomes Sciences, Inc. (HOS), a leader in predictive analytics for healthcare. This acquisition aims to enhance Terumo's digital healthcare capabilities through the ePRISM® platform, which delivers personalized insights for treatment. Expected to close in February 2021, the deal represents a strategic opportunity for Terumo to reduce healthcare costs and improve patient outcomes worldwide. HOS's technology will integrate into Terumo's Business Edge unit, reinforcing its commitment to precision medicine.
Terumo Corporation (TSE: 4543) has completed a clinical study in Japan for an automated injection device developed in collaboration with Kyowa Kirin Co., Ltd. The study initiated in February 2020 aimed to assess the safety of the device combined with G-Lasta®, a drug that reduces febrile neutropenia in chemotherapy patients. This investigational product allows for administration on the same day as chemotherapy, potentially easing hospital visits for patients. Terumo aims to enhance healthcare delivery through innovative drug delivery systems.
IceCure Medical Ltd. (TASE: ICCM) announced an expanded partnership with Terumo Corporation (TRUMY: OTC US) to enhance its reach in Southeast Asia. The agreement grants Terumo exclusive distribution rights for IceCure's ProSense™ cryoablation system in Thailand for six years, with a potential extension. The deal includes a $450,000 payment, with an initial purchase order worth $329,000. IceCure aims to address the high cancer incidence in Thailand, where approximately 170,000 cases are reported annually, leveraging its minimally invasive technology for effective tumor treatment.